tiprankstipranks
Advertisement
Advertisement

PCVX Stock Latest News

Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
The FlyVaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
21d ago
PCVX
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
PremiumThe Fly
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
25d ago
PCVX
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
PremiumCompany Announcements
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
1M ago
PCVX
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
PremiumCompany Announcements
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
2M ago
PCVX
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
PremiumRatings
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
2M ago
PCVX
Vaxcyte price target raised to $89 from $85 at BTIG
PremiumThe FlyVaxcyte price target raised to $89 from $85 at BTIG
2M ago
PCVX
Vaxcyte price target lowered to $133 from $134 at BofA
Premium
The Fly
Vaxcyte price target lowered to $133 from $134 at BofA
2M ago
PCVX
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
Premium
The Fly
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
2M ago
PCVX
Vaxcyte price target raised to $75 from $50 at TD Cowen
PremiumThe Fly
Vaxcyte price target raised to $75 from $50 at TD Cowen
2M ago
PCVX
Vaxcyte Launches New $500 Million ATM Equity Program
PremiumCompany Announcements
Vaxcyte Launches New $500 Million ATM Equity Program
2M ago
8K
PCVX
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
PremiumThe Fly
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
2M ago
PCVX
Is PCVX a Buy, Before Earnings?
PremiumPre-Earnings
Is PCVX a Buy, Before Earnings?
2M ago
PCVX
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors
PremiumCompany AnnouncementsVaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors
2M ago
PCVX
Vaxcyte doses first participants in OPUS-3 trial
Premium
The Fly
Vaxcyte doses first participants in OPUS-3 trial
2M ago
PCVX
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
Premium
Company Announcements
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
2M ago
8K
PCVX
Vaxcyte 11M share Spot Secondary priced at $50.00
PremiumThe Fly
Vaxcyte 11M share Spot Secondary priced at $50.00
2M ago
PCVX
Vaxcyte secondary being re-offered at $50 per share
PremiumThe Fly
Vaxcyte secondary being re-offered at $50 per share
2M ago
PCVX
Vaxcyte offering marketed at $50 per share, Bloomberg says
PremiumThe Fly
Vaxcyte offering marketed at $50 per share, Bloomberg says
2M ago
PCVX
Vaxcyte announces offering of $500M of common stock and warrants
PremiumThe Fly
Vaxcyte announces offering of $500M of common stock and warrants
2M ago
PCVX
Vaxcyte provides update on development of VAX-31 pneumococcal vaccine
PremiumThe FlyVaxcyte provides update on development of VAX-31 pneumococcal vaccine
3M ago
PCVX
Needham ups Vaxcyte target, adds to Conviction List
Premium
The Fly
Needham ups Vaxcyte target, adds to Conviction List
3M ago
PCVX
PHAT
Buy Rating on Vaxcyte: De-Risked VAX-31 Clinical Profile, Strong Cash Position, and Attractive Entry Ahead of 2026 Phase 3 Catalyst
Premium
Ratings
Buy Rating on Vaxcyte: De-Risked VAX-31 Clinical Profile, Strong Cash Position, and Attractive Entry Ahead of 2026 Phase 3 Catalyst
3M ago
PCVX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >